Certified
nuclear medicine physician in México City
Dra. Cecilia Carreras Velázquez
The board-certified nuclear medicine physician in Mexico City brings over 15 years of experience in advanced molecular imaging and targeted radionuclide therapy. Specializing in high-precision procedures such as PSMA PET scans, radioactive iodine (I-131) for thyroid conditions, and Lutetium-177 (Lu-177) theranostics for advanced prostate cancer, she provides cutting-edge care tailored to international patients.
Graduating with Honors from the prestigious Universidad Nacional Autónoma de México (UNAM), she combines rigorous academic excellence with a patient-centered approach. Her commitment to clear communication, safety, and precise diagnostic techniques makes her a leading choice for patients seeking affordable targeted nuclear therapies and medical tourism in Mexico.
Education and certifications of the
Nuclear physician
in México City
- Medical License: 4260509 / 6880062
-Member of the Mexican Federation of Nuclear Medicine and Molecular Imaging (FMMNIM) -Member of the Mexican Board of Nuclear Medicine Physicians (Consejo Mexicano de Médicos Nucleares A.C.) -Member of the Mexican College of Nuclear Medicine Physicians -Member of the European Association of Nuclear Medicine (EANM) -Member of the Latin American Association of Biology and Nuclear Medicine (ALASBIMN) -Member of the North American Neuroendocrine Tumor Society (NANETS) -Member of the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) -Member of the International Centers of Precision Oncology (ICPO) -Mexican Ambassador of the European “Oncidium Foundation” -Board Certified in Nuclear Medicine by the Mexican Board of Nuclear Medicine Physicians (Consejo Mexicano de Médicos Nucleares A.C.) for the 2010–2014 period, with recertifications for 2015–2019, 2020–2024, and 2025–2029 (CVC-226-2010) -Board Certified in Oncologic, Molecular, and Therapeutic Nuclear Medicine by the Mexican Board of Nuclear Medicine Physicians (Consejo Mexicano de Médicos Nucleares A.C.) for the 2012–2016 period, with recertifications for 2017–2021 and 2022–2026